Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408368 | 0.83 | S1PR1 (0.60) | S1PR1S1PR3 | |
| SCHEMBL3210925 | 0.82 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL3211925 | 0.82 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL27859338 | 0.82 | S1PR1 (0.61) | S1PR1S1PR3 | |
| SCHEMBL3402111 | 0.81 | S1PR1 (0.79) | S1PR1S1PR3 | |
| SCHEMBL3402120 | 0.81 | S1PR1 (0.79) | S1PR1S1PR3 | |
| SCHEMBL3408752 | 0.81 | S1PR1 (0.61) | S1PR1S1PR3 | |
| SCHEMBL3401923 | 0.80 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL3401929 | 0.80 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL3404181 | 0.80 | S1PR1 (0.64) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015695-B | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD | 2014-08-27 | — | — | CN | disclosed |
| US-8575200-B2 | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2252609-B1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-17 | — | — | EP | disclosed |
| CN-102015695-A | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD | 2011-04-13 | — | — | CN | disclosed |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-12-30 | — | — | US | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | IL2, FCGRT, CD4 | S1PR1 94/4885S1PR3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.